Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 311,800 Equity Shares on exercise of ESOP05-05-2021
05-05-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Product Approval : US FDA approval for Foscarnet Sodium Injection, 6000 mg/250 mL (24 mg/mL) Single-Dose Bag for Infusion22-04-2021
Sputnik vaccine provides fresh triggers for Gland Pharma
As such, the company's prospects remain strong given the unique business-to-business model it operates on which enables it to grow its market share through multiple marketing partnerships21-04-2021
Gland Pharma hits new high; stock zooms 92% over issue price
The stock was trading higher for the fourth straight day, up 16 per cent during the period20-04-2021
Gland Pharma Ltd - 543245 - Shareholding for the Period Ended March 31, 2021
Gland Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here17-04-2021
Gland Pharma Q4 PAT seen up 17.3% YoY to Rs. 229 cr: Sharekhan
Net Sales are expected to increase by 30 percent Y-o-Y (down 3.9 percent Q-o-Q) to Rs. 825.8 crore, according to Sharekhan.12-04-2021
Gland Pharma Ltd - 543245 - Earnings Conference Call
Earnings Call for Investors/Analysts to be held on Monday, 17th May, 2021 at 1830-1930 hours IST12-04-2021
Gland Pharma Ltd - 543245 - Earnings Conference Call
Earnings Call for Investors/Analysts to be held on Monday, 17th May, 2021 at 1830 hours IST12-04-2021
Gland Pharma Ltd - 543245 - Compliance Certificate For The Half Year Ended 31-March-2021
Compliance Certificate pursuant to Regulation 7(3) of SEBI LODR for the Half Year ended 31-March-202109-04-2021
Gland Pharma Ltd - 543245 - Certificate From Practicing Company Secretary Certifying The Transfer / Transmission / Transposition Of Share Certificates
Certificate from Practicing Company Secretary certifying the transfer / transmission / transposition of share certificates09-04-2021